NEX-18
A new formulation of azacitidine, first-line treatment for MDS (myelodysplastic syndrome), a rare group of bone marrow failure disorders.
Currently on hold Read moreNEX-20
A new formulation of lenalidomide, a core drug in the treatment of Multiple Myeloma, a rare cancer of plasma cells in the bone marrow.
Currently on hold Read moreNEX-22
Sustained-release formulation of liraglutide with one-month release. Liraglutide is a GLP-1 analogue that is usually included in the basic treatment of type 2 diabetes, one of our most common public diseases.
Read morePartner collaborations
In addition to its own product development projects, Nanexa also licenses the PharmaShell technology for other pharmaceutical companies to develop their own long-acting injectables.
Nanexa is continuously developing new and existing relations with potential partners Several companies evaluatesPharmaShell, for example Moderna, Novo Nordisk and AstraZeneca.